Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population

Ethical regulations and limited paediatric participants are key challenges that contribute to a median delay of 6 years in paediatric mAb approval. To overcome these barriers, modelling and simulation methodologies have been adopted to design optimized paediatric clinical studies and reduce patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrew Lim (Author), Pradeep Sharma (Author), Oleg Stepanov (Author), Venkatesh Pilla Reddy (Author)
Format: Book
Published: MDPI AG, 2023-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_106881d25b4247ce8c694e50adc7d02c
042 |a dc 
100 1 0 |a Andrew Lim  |e author 
700 1 0 |a Pradeep Sharma  |e author 
700 1 0 |a Oleg Stepanov  |e author 
700 1 0 |a Venkatesh Pilla Reddy  |e author 
245 0 0 |a Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population 
260 |b MDPI AG,   |c 2023-05-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15051552 
500 |a 1999-4923 
520 |a Ethical regulations and limited paediatric participants are key challenges that contribute to a median delay of 6 years in paediatric mAb approval. To overcome these barriers, modelling and simulation methodologies have been adopted to design optimized paediatric clinical studies and reduce patient burden. The classical modelling approach in paediatric pharmacokinetic studies for regulatory submissions is to apply body weight-based or body surface area-based allometric scaling to adult PK parameters derived from a popPK model to inform the paediatric dosing regimen. However, this approach is limited in its ability to account for the rapidly changing physiology in paediatrics, especially in younger infants. To overcome this limitation, PBPK modelling, which accounts for the ontogeny of key physiological processes in paediatrics, is emerging as an alternative modelling strategy. While only a few mAb PBPK models have been published, PBPK modelling shows great promise demonstrating a similar prediction accuracy to popPK modelling in an Infliximab paediatric case study. To facilitate future PBPK studies, this review consolidated comprehensive data on the ontogeny of key physiological processes in paediatric mAb disposition. To conclude, this review discussed different use-cases for pop-PK and PBPK modelling and how they can complement each other to increase confidence in pharmacokinetic predictions. 
546 |a EN 
690 |a pharmacokinetic modelling 
690 |a PBPK modelling 
690 |a popPK modelling 
690 |a pharmacokinetics 
690 |a pediatrics 
690 |a monoclonal antibodies 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 5, p 1552 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/5/1552 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/106881d25b4247ce8c694e50adc7d02c  |z Connect to this object online.